Dermatology Research Institute

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)9 trials
• Vitiligo7 trials
• Alopecia areata3 trials
• Hidradenitis suppurativa1 trial
• Psoriasis1 trial

Phase

• Phase 315 trials
• Phase 25 trials
• Phase 2/31 trial

Status

• Active, not recruiting9 trials
• Completed6 trials
• Recruiting4 trials
• Enrolling by invitation1 trial
• Terminated1 trial

Lead sponsor

• Pfizer7 trials
• Incyte Corporation5 trials
• Eli Lilly and Company4 trials
• Bluefin Biomedicine, Inc.1 trial
• Bristol-Myers Squibb1 trial
• and 3 more

Running trials

• Active, not recruiting

  A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

  NCT07265479· Phase 3· Organon and Co· Source

• Recruiting

  A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  NCT07216027· Phase 2· Pfizer· Source

• Active, not recruiting

  A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

  NCT07228390· Phase 2· Pfizer· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Bristol-Myers Squibb· Source

  Contact: Vimal Prajapati, Site 0013

• Active, not recruiting

  A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

  NCT07105488· Phase 2· Bluefin Biomedicine, Inc.· Source

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

  NCT06163326· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

  NCT06113445· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

  NCT06072183· Phase 3· Pfizer· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

  NCT05723198· Phase 3· Eli Lilly and Company· Source

  Contact: Vimal Prajapati (principal investigator)

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

  NCT03898479· Phase 2/3· Sun Pharmaceutical Industries, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)2 recruiting
• Alopecia areata1 recruiting
• Psoriasis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

  NCT06493578· Phase 2· Vyne Therapeutics Inc.· Source

• Completed

  A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

  NCT05750823· Phase 2· Incyte Corporation· Source

• Completed

  A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

  NCT05583526· Phase 3· Pfizer· Source

• Completed

  Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

  NCT05456529· Phase 3· Incyte Corporation· Source

• Completed

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

  NCT04921969· Phase 3· Incyte Corporation· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source